| |
|
|
|
|
|
|
|||
|
Blood, 1 January 2008, Vol. 111, No. 1, pp. 209-218. Prepublished online as a Blood First Edition Paper on September 17, 2007; DOI 10.1182/blood-2007-04-082552.
IMMUNOBIOLOGY Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1)1 Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD; 2 Medical Research Council (MRC) Immunohistochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, United Kingdom; 3 Servicio de Inmunologia, Hospital Nacional de Pediatria J. P. Garrahan, Buenos Aires, Argentina; 4 Department of Medicine, Duke University Medical Center, Durham, NC; 5 Laboratory of Host Defenses, NIAID, NIH, Bethesda, MD; 6 Genetics and Molecular Biology Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD; 7 Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD; and 8 School of Biological Sciences, Nanyang Technological University, Singapore Leukocyte adhesion deficiency type-1 (LAD-1) is an autosomal recessive immunodeficiency caused by mutations in the β2 integrin, CD18, that impair CD11/CD18 heterodimer surface expression and/or function. Absence of functional CD11/CD18 integrins on leukocytes, particularly neutrophils, leads to their incapacity to adhere to the endothelium and migrate to sites of infection. We studied 3 LAD-1 patients with markedly diminished neutrophil CD18 expression, each of whom had a small population of lymphocytes with normal CD18 expression (CD18+). These CD18+ lymphocytes were predominantly cytotoxic T cells, with a memory/effector phenotype. Microsatellite analyses proved patient origin of these cells. Sequencing of T-cell subsets showed that in each patient one CD18 allele had undergone further mutation. Interestingly, all 3 patients were young adults with inflammatory bowel disease. Somatic reversions of inherited mutations in primary T-cell immunodeficiencies are typically associated with milder clinical phenotypes. We hypothesize that these somatic revertant CD18+ cytotoxic T lymphocytes (CTLs) may have altered immune regulation. The discovery of 3 cases of reversion mutations in LAD-1 at one center suggests that this may be a relatively common event in this rare disease.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||